Clinical trials
Newly Diagnosed clinical trials
Below are recruiting newly diagnosed clinical trials, each written for real people, not researchers. We’re tracking 395 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07159620RecruitingPhase 2
New drug combo for rare leukemia type (ETP-ALL)
This trial tests a combination of drugs (venetoclax, azacitidine, chidamide, vindesine, and dexamethasone) in people newly diagnosed with a rare subtype of T-cell acute lymphoblastic leukemia called ETP-ALL or near-ETP-ALL. The goal is to see if this drug cocktail can improve outcomes.
Suzhou, JiangsuAges 14–65 - NCT07188441RecruitingPhase 2
Treating newly diagnosed central malignant germ cell tumors with teniposide and cisplatin
This trial tests a combination of two chemotherapy drugs—teniposide and cisplatin—for people who have just been diagnosed with a malignant germ cell tumor in the brain. The goal is to see if this treatment is safe and effective.
Guangzhou, GuangdongAges 5 years+ - NCT07208981RecruitingPhase 2
Orelabrutinib, zebetuzumab, and lenalidomide for new MZL
This trial tests a combination of three drugs (orelabrutinib, zebetuzumab, and lenalidomide) for people newly diagnosed with a type of lymphoma called marginal zone lymphoma (MZL). If you qualify, you may receive this treatment to help control the disease.
Nanjing, JiangsuAges 18–75 - NCT07224100RecruitingPhase 2
Chemo plus targeted drug for newly diagnosed Ph+ ALL
This trial tests a combination of chemotherapy drugs (EPOCH) plus a targeted therapy (ponatinib) for patients with a specific type of acute lymphoblastic leukemia (Ph+ ALL). Some participants also get rituximab if their leukemia cells have a certain marker (CD20). The goal is to see how well this treatment works as a first therapy.
Seattle, WashingtonAges 18 years+ - NCT07224321RecruitingPhase 2
Inhaled insulin for youth with new type 1 diabetes
This trial tests an inhaled insulin called Afrezza for teenagers and pre-teens who were just diagnosed with type 1 diabetes. It compares a combination of Afrezza and long-acting insulin injections to the usual insulin pen or pump therapy, to see if it helps control blood sugar and is safe for young people.
Los Angeles, CaliforniaAges 10–17 - NCT07235904RecruitingPhase 4
Mirikizumab vs standard treatment for newly diagnosed ulcerative colitis
This trial tests if starting with the stronger drug mirikizumab (top-down therapy) works better than the usual treatment with azathioprine for people newly diagnosed with moderate-to-severe ulcerative colitis. It aims to see which approach controls inflammation and improves symptoms faster.
KielAges 18–75 - NCT03150693RecruitingPhase 3
New treatment for young adults with CD22-positive ALL
This Phase 3 trial tests adding inotuzumab ozogamicin to standard chemotherapy for newly diagnosed CD22-positive B-cell acute lymphoblastic leukemia (ALL). It may help more patients achieve remission and reduce the risk of the leukemia coming back, while also checking safety and tolerability.
Birmingham, AlabamaAges 18–39 - NCT07585760RecruitingPhase 2
Study of CM336 and Isatuximab for new multiple myeloma with kidney problems
This trial tests a combination of two drugs, CM336 and Isatuximab, for people newly diagnosed with multiple myeloma that has caused kidney damage. The goal is to see if this treatment can help control the myeloma while also addressing the kidney issues.
TianjinAges 18–80 - NCT07680933RecruitingPhase 2
Orelabrutinib plus chemo for newly diagnosed DLBCL
This trial tests if adding orelabrutinib (a targeted pill) to standard chemotherapy, with or without a stem cell transplant, works better for people with a new diagnosis of diffuse large B-cell lymphoma. It may help patients who have a higher risk of the lymphoma coming back.
Xuzhou, JiangsuAges 18–80 - NCT07259707RecruitingPhase 2
Gilteritinib with chemotherapy for FLT3-ITD positive AML
This trial tests if adding the targeted drug gilteritinib to standard chemotherapy improves outcomes for adults with a specific type of AML (FLT3-ITD+). It's for newly diagnosed patients who can tolerate intensive treatment.
Hangzhou, ZhejiangAges 18–59 - NCT07280416Recruiting
Sleep changes in first year after cancer diagnosis
This study follows people who are newly diagnosed with cancer to see how their sleep changes during the first year. It looks at whether treatments like chemo or immunotherapy affect insomnia.
Le Puy-en-VelayAges 18–80 - NCT07284069RecruitingEarly Phase 1
Senicapoc and perampanel for newly diagnosed glioblastoma
This trial tests two drugs, senicapoc and perampanel, added to standard treatment for people with newly diagnosed glioblastoma. The goal is to see if they can help slow tumor growth or improve outcomes.
Aarhus, DenmarkAges 18 years+ - NCT07297329RecruitingPhase 3
Newly diagnosed multiple myeloma trial for transplant-ineligible patients
This trial tests a new drug called SCTC21C combined with standard treatments (bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see if this combination is safe and works better than current options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07333261RecruitingPhase 1
Study of BMS-986453 for newly diagnosed multiple myeloma
This trial tests a new drug, BMS-986453, for people newly diagnosed with multiple myeloma. It aims to see if the drug is safe and works well for those who cannot or choose not to have a stem cell transplant.
Birmingham, AlabamaAges 19 years+ - NCT07343986RecruitingPhase 1
Ultrasound and Immunotherapy for Newly Diagnosed Brain Cancer
This trial tests whether a special ultrasound (LIFU) can open the blood-brain barrier to help an immunotherapy drug (cetuximab) reach glioblastoma tumors better. It is for people with a specific type of glioblastoma that has not been treated yet and that has a certain protein called EGFR.
Charlottesville, VirginiaAges 18–70 - NCT06805305RecruitingPhase 2
Immunotherapy for newly diagnosed glioblastoma
This trial tests a new personalized immunotherapy (DOC1021) for people with newly diagnosed glioblastoma. The treatment uses your own immune cells to attack the tumor and is given after surgery and with standard chemotherapy and radiation.
Gilbert, ArizonaAges 18 years+ - NCT07670130Recruiting
Venetoclax TDM in Newly Diagnosed AML: Response and Outlook
This study looks at how the drug venetoclax works in people newly diagnosed with acute myeloid leukemia (AML). It helps doctors understand the right dose for better results.
SuzhouAges 16 years+ - NCT07346144RecruitingPhase 1/Phase 2
Gene therapy study for high-grade glioma
This trial tests a new gene therapy given directly into the brain tumor. It's for people with high-grade glioma, either newly diagnosed or after one recurrence, to see if it can help control the tumor.
Columbus, OhioAges 18–70 - NCT07359911Recruiting
Exercise program for teens and young adults with sarcoma starting chemo
This study tests whether a special exercise program can help young people with sarcoma better tolerate chemotherapy. It may improve how well they respond to treatment and reduce side effects.
Miami, FloridaAges 12–39 - NCT07366879Recruiting
Exercise program for newly diagnosed pulmonary hypertension
This study tests whether a home-based exercise program, added to your regular medications, can help people who are newly diagnosed with pulmonary arterial hypertension feel better and improve their daily function.
GlasgowAges 18 years+ - NCT07371923RecruitingPhase 2
Zanubrutinib combination therapy for newly diagnosed high-risk DLBCL
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07374328RecruitingPhase 1/Phase 2
Three diabetes medicines for new type 2 diabetes
This trial tests a combination of three diabetes medicines to see if they can quickly get high blood sugar under control in people newly diagnosed with type 2 diabetes. It's designed for those whose HbA1c is 9.0% or higher.
Guangzhou, GuangdongAges 18–65 - NCT07375992Recruiting
Music therapy for newly diagnosed glioblastoma
This trial tests whether attending virtual music therapy sessions can help people with newly diagnosed glioblastoma feel better after chemoradiation. It aims to improve quality of life and emotional well-being.
Baltimore, MarylandAges 18 years+ - NCT07383246RecruitingPhase 3
FAPI-guided surgery for newly diagnosed medullary thyroid cancer
This trial tests whether a special imaging agent (FAPI) can help surgeons remove medullary thyroid cancer more precisely during your first surgery. It is for people who have not yet been treated and are scheduled for surgery within 30 days.
Beijing, Beijing MunicipalityAges Any age
Hear when a new Newly Diagnosed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for newly diagnosed?
- Yes. Clin2 currently lists 395 recruiting newly diagnosed studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a newly diagnosed trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a newly diagnosed trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.